WHO ICTRP trial
A Clinical Study to Evaluate the Safety and Efficacy of fixed dose combination…
CTRI/2022/06/043453 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2022/06/043453 |
|---|---|
| Public title | A Clinical Study to Evaluate the Safety and Efficacy of fixed dose combination of L-Ornithine-L-Aspartate 150 mg, Pancreatin IP 100mg enteric coated tablets as supportive and maintenance therapy in hepatitis |
| Scientific title | Evaluation of Safety and Efficacy of fixed dose combination of L-Ornithine-L-Aspartate 150 mg, Pancreatin IP 100mg enteric coated tablets as supportive and maintenance therapy in hepatitis: A Phase IV, Prospective, Open Label, Multi-centric, Single Arm, Clinical Study. - Hepamerz |
| Primary sponsor | Win Medicare Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | India |
| Conditions | Health Condition 1: K768- Other specified diseases of liver |
| Interventions | Intervention1: fixed dose combination of L-Ornithine-L-Aspartate 150 mg, Pancreatin IP 100mg enteric coated tablets: Mode and frequency of administration - 2 tablets three times daily after meals. Tablets should be swallowed whole with… |
| Registration date | Jun 23, 2022 |
| Target size | 220 |
| Secondary IDs | CT- CE-HM- 2022/Version 3.0/Dated- 04-Apr-2022 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: